MorphoSys Grants ImmunoGen Access to HuCAL GOLD®

02-Jun-2005

MorphoSys AG announced that the US biotechnology company, ImmunoGen Inc., has licensed access to the MorphoSys HuCAL GOLD® library for use in ImmunoGen's internal target research programs. ImmunoGen will pay MorphoSys subscription fees during the one-year term of the agreement. Further financial details were not disclosed.

In June 2001, ImmunoGen and MorphoSys entered into a collaboration to use MorphoSys's previous version of the HuCAL® library (Human Combinatorial Antibody Library) in ImmunoGen's internal research programs. The four-year term of this prior agreement ended in May 2005.

The two companies also have a separate collaboration, established in September 2000, to develop a fully human antibody against an ImmunoGen-provided cell-surface target associated with various forms of cancer.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances